It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Disc ...

BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $28.79 which represents a slight increase of $2.13 or 7.99% from the prior close of $26.66. The stock opened at $26.96 and ...

(NASDAQ: BBIO) recently announced that the U.S. Food and Drug Administration (FDA ... Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus ...

GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...

The candidate has been approved under the brand name Attruby. BBIO stock surged 16.1% on the FDA approval of the drug. BridgeBio’s shares have lost 32.6% in the year-to-date period against the ...

The candidate has been approved under the brand name Attruby. BBIO stock surged 16.1% on the FDA approval of the drug. BridgeBio’s shares have lost 32.6% in the year-to-date period against the ...